TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maintaining Nonsmoking: Older Smokers - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
smokers of at least 10 cigarettes per day~Inclusion Criteria:~MULTIPLE~Exclusion Criteria:~MULTIPLE

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Brief Treatment (Type: ACTIVE_COMPARATOR): Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT)~Brief Counseling - The counseling intervention consisted of five 90-minute group meetings.~There was no further treatment during Weeks 12-52.
- Extended NRT (Type: EXPERIMENTAL): Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT.~Counseling Treatment - This is identical to the Brief Counseling described above.
- Tailored/No Extended NRT (Type: EXPERIMENTAL): This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
- Extended Tailored Counseling + NRT (Type: EXPERIMENTAL): Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WIC-Based Intervention to Promote Healthy Eating Among Low-Income Mothers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English- or Spanish-speaking~* Farmers' Market Nutrition Program (FMNP) voucher recipient or caregiver of a child FMNP voucher recipient~* Not less than 3 months from expected delivery date (pregnant women)~* Eligible to receive WIC benefits for 6 months after study entry~Exclusion Criteria:~● Restrictions of food intake (has food allergies or foods that cannot be eaten)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): This group will receive routine services provided by WIC and an intervention that will combine behaviorally-focused nutrition education with 1) the establishment of a WIC-based farmers' market (implemented in 2019 during the WIC Farmers' Market Nutrition Program voucher issuance period \[June 19 to August 19\]), and 2) monthly trips to an area farmers' market (between September 1, 2019 and November 30, 2019 \[the end of the local growing season\]).
- Control (Type: NO_INTERVENTION): This group will receive routine services provided by WIC only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a child who is 3 years old; have custody of child; endorse at least 3 symptom criteria of BPD in which one symptom must be affective instability and uncontrollable anger; have a verbal IQ of at least 70~Exclusion Criteria:~* Does not have custody of child; child has known developmental disabilities; mother is psychotic; mother has suicidal ideation + an active plan; mother has low verbal IQ

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dialectical Behavior Therapy Skills (Type: EXPERIMENTAL): Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
- Family Services as Usual (Type: NO_INTERVENTION): Mothers will continue with services they are receiving in the community

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 - 75, inclusive~* Diagnosed with type 2 diabetes~* Hemoglobin A1c value greater than or equal to 8.0%~* Antidiabetic treatments may include sulfonylurea agents (non-sulfonylurea agents must be withdrawn)~* Overweight, obese (body mass index 25-45 kg/m2)~Exclusion Criteria:~* Change of dose of lipid or blood pressure lowering therapy within past three months~* Previous treatment with colesevelam for hyperlipidemia~* Serum triglyceride greater than 500 mg/dL~* Serum low density lipoprotein-cholesterol less than 60 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): colesevelam 3.8g administered daily for 12 weeks
- 2 (Type: PLACEBO_COMPARATOR): Colesevelam matching placebo for 12 weeks
- 3 (Type: ACTIVE_COMPARATOR): open-label Insulin Glargine for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abdominal Colpopexy: Comparison of Endoscopic Surgical Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Stage II to IV pelvic organ prolapse~2. Prolapse of the vaginal apex or cervix to at least half way into the vaginal canal~3. Vaginal bulge symptoms~4. Minimally invasive surgery is planned~5. Available for 12 months of follow-up~6. Able to complete study assessments~7. Able and willing to provide written informed consent~Exclusion Criteria:~1. Contraindication to laparoscopic or robotically assisted laparoscopic abdominal sacrocolpopexy~2. Subject wishes to retain her uterus (i.e., surgical assignment may involve removal of uterus, if not previously removed)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laparoscopic Abdominal Sacrocolpopexy (LASC) (Type: ACTIVE_COMPARATOR): Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC)
- Robotic Assisted Laparoscopic (RASC) (Type: EXPERIMENTAL): Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Care Ecosystem: Navigating Patients and Families Through Stages of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
This study will enroll patients as well as their primary caregivers as research participants.~Inclusion criteria for patient participants:~1. Patient has a diagnosis of dementia with a progressive course~2. Patient has a primary caregiver (identified as having primary responsibility for patient) that is eligible for and agrees to join the study~3. Patient is covered by Medicare or Medi-caid or is Medi-pending~4. Patient is expected to live at least 3 months based on assessment by the referring provider, the patient's primary care provider, or medical record review~5. Patient speaks either English, Cantonese, Mandarin, or Spanish~6. Patient lives in California or Nebraska or Iowa~7. Patient is age 45 or older~Inclusion criteria for caregiver participants:~1. Caregiver has primary responsibility for dementia patient that is eligible for and agrees to join the study~2. Caregiver speaks either English, Cantonese, Mandarin, or Spanish~3. Caregiver is a legal adult~Exclusion Criteria:~1. Patient resides in a nursing home or skilled nursing facility at time of enrollment~2. Participant is enrolled in a similar clinical trial that precludes their participation in our trial~3. Patient is pregnant

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Navigated Care (Type: EXPERIMENTAL): Comprehensive longitudinal continuing care program
- Survey of Care (Type: NO_INTERVENTION): Control group that will undergo the same regular assessments as patients enrolled in Navigated Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed OAML~* Non-conjunctival or bilateral conjunctival (TNM-based, above T1N0M0 or bT1N0M0), Ann Arbor stage I and II OAML~* Previously untreated~* Age ≥18 years~* Performance status: ECOG 0-2~* Adequate hematological function: hemoglobin ≥9 g/dL,, absolute neutrophil count (ANC) ≥1,500/μL, and platelet count ≥100,000/μL, unless abnormalities are due to bone marrow involvement by the lymphoma~* Adequate liver function tests:~  i. Transaminase (AST/ALT) \<3 times the upper normal value ii. Bilirubin \<2 times the upper normal value~* Adequate renal function:serum creatinine level \<2 mg/dL (177 μmol/L)~* Life expectancy ≥ 6 months~* A negative serum or urine pregnancy test before treatment must be available for both premenopausal women and for women who have \<2 years after the onset of menopause.~* Informed consent~Exclusion Criteria:~* NHL subtypes other than OAML~* Primary conjunctival OAML, unilateral involved (T1N0M0)~* Ann Arbor stage III or IV~* CNS involvement by the lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks) with clinical suspicion of CNS involvement by the lymphoma~* Pregnant or lactating women, women of child-bearing potential not using adequate contraception~* Inadequate liver function tests:~  i. Transaminase (AST/ALT) ≥3 times the upper normal value or ii. Bilirubin ≥2 times the upper normal value~* Inadequate renal function:~  i. serum creatinine level \<2 mg/dL (177 μmol/L)~* Other serious illness or medical conditions i. Unstable cardiac disease despite treatment; myocardial infarction within 6 months prior to study entry ii. History of significant neurological or psychiatric disorders including dementia or seizures~* Active uncontrolled infection (HIV, hepatitis B, Hepatitis C, active Tuberculosis, active bacterial, or active fungal infection)~* Any other malignancies within the past 5 years except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri~* Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies)~* Concomitant administration of any other experimental drug under investigation or concomitant chemotherapy, hormonal therapy, or immunotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-CVP (Type: EXPERIMENTAL): 6 cycles of R-CVP followed by 2 cycles of rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Triiodothyronine for Infants Less Than 5 Months & Malnourished Children Undergoing Cardiopulmonary Bypass in Indonesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children undergoing cardiopulmonary bypass~* Age 3 years old or less~* Aristotle score 6 and above~* Total correction or biventricular repair~Exclusion Criteria:~* Single ventricle defects~* Body weight less than 2 kg at the time of recruitment~* Presentation with sepsis~* Tachyarrhythmia or any other arrhythmia before surgery~* Creatinine level of more than 2 mg/dL~* Known thyroid disease~* Known lung abnormalities (incl. infection) before surgery.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Tetronine (Type: EXPERIMENTAL): Oral T3 (Tetronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Gestation of at least 16 weeks and \<37 weeks;~* P. falciparum monoinfection of any density, with or without symptoms~* Hb equal or higher than 7 g/dL;~* At least 15 years old;~* Residence within the health facility catchment's area;~* Willing to deliver at the health facility;~* Willing to adhere to study requirements (including in Zambia and Malawi, HIV VCT)~* Ability to provide written informed consent; if the woman is minor of age/not emancipated, the consent must be given by a parent or legal guardian according to national law (however, in this case, the investigator is responsible to check that the woman herself is also freely willing to take part in the study, and the woman will be asked to sign for assent).~Exclusion Criteria:~* History of allergic reactions to the study drugs;~* History of known pregnancy complications or bad obstetric history such as repeated stillbirths or eclampsia;~* History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus, severe renal or heart disease, or active tuberculosis;~* Current cotrimoxazole prophylaxis or ARV treatment;~* Any significant illness at the time of screening that requires hospitalization, including severe malaria;~* Intent to move out of the study catchment area before delivery or deliver at relative's home out of the catchment area.~* Prior enrollment in the study or concurrent enrollment in another study.~* Unable to take oral medication~* Clear evidence of recent (1 week) treatment with antimalarials or antimicrobials with antimalarial activity (clindamycin; azythromycin; etc.)

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHAPQ (Type: EXPERIMENTAL): Three-day treatment with dihydroartemisinin-piperaquine
- MQAS (Type: EXPERIMENTAL): Three-day treatment with mefloquine artesunate
- AQAS (Type: ACTIVE_COMPARATOR): Three-day treatment with artesunate-amodiaquine
- AL (Type: ACTIVE_COMPARATOR): Three day treatment with artemether-lumefantrine (Coartem(R)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of bacterial vaginosis~* Women aged 18-55 years~Exclusion Criteria:~* Pregnancy or lactation~* Uterine bleeding (including menstruation but not including cervical contact bleeding on sampling) or vaginal bleeding of unknown origin~* Acute infections of the upper genital tract~* Clinical Symptoms of a vulvovaginal Candidiasis~* Use of anti-infectives (local or systemic) in the previous 14 days and/or during the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Dequalinium chloride 10mg (Type: EXPERIMENTAL): None
- clindamycin vaginal cream 2% (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized for mania with a score \>=20 on the Young Mania Rating Scale (YMRS). (Patients with symptoms of depression are eligible)~* diagnosis of Bipolar Disorder according to Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)~* receiving treatment with a mood stabilizer for a minimum of 2 weeks prior to study initiation, or beginning therapy with a mood stabilizer prior to treatment with study medication~* patients medically stable on the basis of physical examination, medical history and electrocardiogram results.~Exclusion Criteria:~* Other Axis I DSM-IV diagnosis (except nicotine or caffeine dependence)~* history of alcohol or drug abuse or dependence within 3 months of starting the study~* seizure disorder requiring medication~* known sensitivity to risperidone, lithium, valproate or carbamazepine~* pregnant or nursing females, or those lacking adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TDM of Generic Lopinavir/Ritonavir 200/50 mg

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Evidence of HIV infection (confirmed positive ELISA and/or documented history of measurable HIV RNA)~3. Age\> 18 years~4. On a standard PI containing HAART regimen with 2 NRTIs with a VL \< 50 copies for at least 12 weeks OR ARV-naive patients, or patient on a NNRTI based regimen~5. Currently having no AIDS defining illness~6. Willing to adhere to the protocol requirements~Exclusion Criteria:~1. Any history of taking CYP450 inhibitors or inducers, or any gastric acid-reducing drugs within 14 days of enrollment in the study~2. Current pregnancy or lactating~3. Active opportunistic infection~4. ALT/ AST more than 2 x upper limit~5. creatinine more than 1.5 time the upper limit~6. Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion~7. History of sensitivity/idiosyncrasy to the drug or chemically related compounds or excipients which may be employed in the study.~8. Active drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Daily intake of low-dose Aspirin (ASA) - The subject must fulfill at least one of the following (a-e):~* Aged ≥65 years.~* Aged ≥18 years and with a documented history of uncomplicated peptic ulcer(s).~* Aged ≥60 years and naïve to low-dose ASA (ie, treatment started within 1 month prior to randomization).~* Aged ≥60 years and with stable coronary artery disease.~* Aged ≥60 years and with complaints of upper gastrointestinal (GI) symptoms that, as judged by the investigator, requires an Esophagogastroduodenoscopy (EGD) and with the finding of ≥5 gastric and/or duodenal erosions at the baseline endoscopy.~Exclusion Criteria:~* Peptic ulcer(s) at baseline esophagogastroduodenoscopy (EGD).~* Reflux esophagitis Los Angeles (LA) classification grade C or D at baseline~* History of peptic ulcer complications such as clinically significant bleeding and/or perforation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole 40 mg (Type: EXPERIMENTAL): Esomeprazole 40 mg
- Esomeprazole 20 mg (Type: EXPERIMENTAL): Esomeprazole 20 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete